Market Research Logo

Venous (Vein) Thrombosis - Pipeline Review, H2 2015

Venous (Vein) Thrombosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Venous (Vein) Thrombosis - Pipeline Review, H2 2015’, provides an overview of the Venous (Vein) Thrombosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous (Vein) Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous (Vein) Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Venous (Vein) Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Venous (Vein) Thrombosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Venous (Vein) Thrombosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Venous (Vein) Thrombosis Overview
Therapeutics Development
Pipeline Products for Venous (Vein) Thrombosis - Overview
Pipeline Products for Venous (Vein) Thrombosis - Comparative Analysis
Venous (Vein) Thrombosis - Therapeutics under Development by Companies
Venous (Vein) Thrombosis - Therapeutics under Investigation by Universities/Institutes
Venous (Vein) Thrombosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Venous (Vein) Thrombosis - Products under Development by Companies
Venous (Vein) Thrombosis - Products under Investigation by Universities/Institutes
Venous (Vein) Thrombosis - Companies Involved in Therapeutics Development
3SBio Inc.
Archemix Corp.
Astellas Pharma Inc.
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Generex Biotechnology Corporation
Johnson & Johnson
Laboratorios Farmaceuticos Rovi, S.A.
Merrion Pharmaceuticals Plc
Nihon Pharmaceutical Industry Co., Ltd.
Venous (Vein) Thrombosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AB-012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense RNAi Oligonucleotide for DVT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
apixaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARC-15105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-1468240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-5539 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enoxaparin biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ER-410660 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fondaparinux sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fondaparinux sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-375 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPB-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Hematological Disorders and Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venous (Vein) Thrombosis - Recent Pipeline Updates
Venous (Vein) Thrombosis - Dormant Projects
Venous (Vein) Thrombosis - Discontinued Products
Venous (Vein) Thrombosis - Product Development Milestones
Featured News & Press Releases
Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015
Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting
Jun 15, 2015: New Clinical Data Further Supporting the Positive Benefit Risk Profile of Bayer’s Xarelto and Real Life Insights to be Presented at ISTH 2015
May 04, 2015: Bayer’s Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis
Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents
Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Venous (Vein) Thrombosis, H2 2015
Number of Products under Development for Venous (Vein) Thrombosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Venous (Vein) Thrombosis - Pipeline by 3SBio Inc., H2 2015
Venous (Vein) Thrombosis - Pipeline by Archemix Corp., H2 2015
Venous (Vein) Thrombosis - Pipeline by Astellas Pharma Inc., H2 2015
Venous (Vein) Thrombosis - Pipeline by Bayer AG, H2 2015
Venous (Vein) Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Venous (Vein) Thrombosis - Pipeline by Eisai Co., Ltd., H2 2015
Venous (Vein) Thrombosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Venous (Vein) Thrombosis - Pipeline by Generex Biotechnology Corporation, H2 2015
Venous (Vein) Thrombosis - Pipeline by Johnson & Johnson, H2 2015
Venous (Vein) Thrombosis - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2015
Venous (Vein) Thrombosis - Pipeline by Merrion Pharmaceuticals Plc, H2 2015
Venous (Vein) Thrombosis - Pipeline by Nihon Pharmaceutical Industry Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Venous (Vein) Thrombosis Therapeutics - Recent Pipeline Updates, H2 2015
Venous (Vein) Thrombosis - Dormant Projects, H2 2015
Venous (Vein) Thrombosis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Venous (Vein) Thrombosis, H2 2015
Number of Products under Development for Venous (Vein) Thrombosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report